Have a feature idea you'd love to see implemented?
Let us know!
ORIC Oric Pharmaceuticals Inc
Price (delayed)
$9.12
Market cap
$643.57M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$1.81
Enterprise value
$599.34M
ORIC Pharmaceuticalsis a clinical stage biopharmaceutical company dedicated to improving patients' lives by Overcoming Resistance In Cancer. ORIC's lead product candidate, ORIC-101, is a potent and selective small molecule antagonist
Highlights
The quick ratio has declined by 13% since the previous quarter but it has grown by 7% year-on-year
Oric Pharmaceuticals's equity has increased by 11% YoY but it has decreased by 9% QoQ
ORIC's net income is down by 29% year-on-year and by 8% since the previous quarter
Key stats
What are the main financial stats of ORIC
Market
Valuations
Earnings
Shares outstanding
70.57M
Market cap
$643.57M
Enterprise value
$599.34M
Price to earnings (P/E)
N/A
Price to book (P/B)
2.35
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
EBIT
-$119.87M
EBITDA
-$118.8M
Free cash flow
-$109.9M
Per share
Balance sheet
Liquidity
EPS
-$1.81
Free cash flow per share
-$1.56
Book value per share
$3.88
Revenue per share
$0
TBVPS
$4.28
Total assets
$302.07M
Total liabilities
$28.08M
Debt
$0
Equity
$273.99M
Working capital
$258.18M
Debt to equity
0
Current ratio
13.15
Quick ratio
12.82
Net debt/EBITDA
0.37
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-38.9%
Return on equity
-42.5%
Return on invested capital
-48.8%
Return on capital employed
-42.7%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
ORIC stock price
How has the Oric Pharmaceuticals stock price performed over time
Intraday
4.35%
1 week
3.28%
1 month
0%
1 year
28.27%
YTD
-0.87%
QTD
-11.02%
Financial performance
How have Oric Pharmaceuticals's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$134.75M
Net income
-$119.87M
Gross margin
N/A
Net margin
N/A
The operating income has declined by 33% year-on-year and by 8% since the previous quarter
ORIC's net income is down by 29% year-on-year and by 8% since the previous quarter
Growth
What is Oric Pharmaceuticals's growth rate over time
Valuation
What is Oric Pharmaceuticals stock price valuation
P/E
N/A
P/B
2.35
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The EPS has increased by 9% year-on-year but it has declined by 2.8% since the previous quarter
Oric Pharmaceuticals's equity has increased by 11% YoY but it has decreased by 9% QoQ
The stock's P/B is 7% more than its 5-year quarterly average of 2.2 and 2.2% more than its last 4 quarters average of 2.3
Efficiency
How efficient is Oric Pharmaceuticals business performance
The ROA has declined by 8% year-on-year and by 6% since the previous quarter
Oric Pharmaceuticals's return on invested capital has decreased by 7% QoQ but it has increased by 6% YoY
The return on equity has declined by 7% year-on-year and by 6% since the previous quarter
Dividends
What is ORIC's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for ORIC.
Financial health
How did Oric Pharmaceuticals financials performed over time
The quick ratio has declined by 13% since the previous quarter but it has grown by 7% year-on-year
The company's current ratio fell by 13% QoQ but it rose by 7% YoY
ORIC's debt is 100% smaller than its equity
Oric Pharmaceuticals's equity has increased by 11% YoY but it has decreased by 9% QoQ
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.